Cardiff Oncology/$CRDF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Ticker
$CRDF
Sector
Primary listing
Employees
31
Headquarters
Website
Cardiff Oncology Metrics
BasicAdvanced
$131M
-
-$0.69
1.34
-
Price and volume
Market cap
$131M
Beta
1.34
52-week high
$4.56
52-week low
$1.48
Average daily volume
761K
Financial strength
Current ratio
3.668
Quick ratio
3.586
Long term debt to equity
0.225
Total debt to equity
1.833
Profitability
EBITDA (TTM)
-48.596
Gross margin (TTM)
-300.67%
Net profit margin (TTM)
-7,732.04%
Operating margin (TTM)
-8,256.32%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-38.47%
Return on equity (TTM)
-71.45%
Valuation
Price to revenue (TTM)
216.436
Price to book
2.89
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
-3.38
Free cash flow yield (TTM)
-29.58%
Free cash flow per share (TTM)
-0.568
Growth
Revenue change (TTM)
-13.18%
Earnings per share change (TTM)
-28.05%
3-year revenue growth (CAGR)
15.39%
10-year revenue growth (CAGR)
6.60%
3-year earnings per share growth (CAGR)
-8.24%
10-year earnings per share growth (CAGR)
-38.37%
What the Analysts think about Cardiff Oncology
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Revenues and expenses
Cardiff Oncology Earnings Performance
Company profitability
Cardiff Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $131M as of March 18, 2026.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of March 18, 2026.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.